News
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...
In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...
For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.
2d
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results